Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Language
Publication year range
1.
Chinese Medical Journal ; (24): 402-404, 2002.
Article in English | WPRIM (Western Pacific) | ID: wpr-308075

ABSTRACT

<p><b>OBJECTIVE</b>To study the effect of dehydroepiandrosterone sulfate (DHEAS) treatment of osteoporosis in men with T(BMD) > or = 2.5SD.</p><p><b>METHODS</b>Eighty-six patients were randomly divided into two groups: treatment group (n = 44) and control group (n = 42). DHEAS (100 mg q.d.) was given to the treatment group for 6 months. Bone mineral density, (BMD), biochemical markers of bone absorption and formation and other serum biochemical markers were measured before and after DHEAS treatment. Drug side effects were also evaluated.</p><p><b>RESULTS</b>After oral administration of DHEAS (100 mg q.d.) for 6 months, the serum concentrations of DHEAS and IGF-I in the treatment group were 93.75% +/- 16.1% and 17.71% +/- 4.2% higher respectively than those in the control group (P < 0.01). The BMD of L2, L3, L4, L2 - 4 and Neck sections increased in the treatment group by 2.65% +/- 0.65%, 2.70% +/- 0.48%, 3.10% +/- 0.41%, 2.82% +/- 0.37% and 2.32% +/- 0.31%, respectively, as compared with that the control group (P < 0.05 or 0.01). No significant changes were observed in serum FT, E(2) and PSA concentrations in the treatment group as compared with the control group.</p><p><b>CONCLUSION</b>The treatment of osteoporosis in men with DHEAS is safe and effective.</p>


Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Bone Density , Dehydroepiandrosterone Sulfate , Therapeutic Uses , Osteoporosis , Drug Therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...